guidelines for recruiting, selection, and training of agency personnel; (11) develops and directs research and evaluation studies to focus on, and improve the effectiveness of, OEEO program activities; (12) provides direction for the agency’s alternative dispute resolution activities; and (13) provides direct support for OEEO program activities in CDC.

Delete in its entirety the functional statement for the Office of Minority Health and Health Equity (CAW), and insert the following:

Office of Minority Health and Health Equity (CAW). In carrying out its mission, the Office of Minority Health and Health Equity: (1) Accelerates the work of CDC and its partners in improving health by eliminating health disparities, promoting conditions conducive to health, and achieving health equity; (2) provides leadership and support for the agency’s research, policy, and prevention initiatives to promote and improve the health of women and girls; (3) ensures CDC’s diversity policies, procedures and practices support employees in reaching their full potential so that they may better accomplish CDC’s mission and be effective guardians of public health.

Minority Health and Health Equity Activity (CAW12). (1) Reframes eliminating health disparities as achievable; (2) facilitates the implementation of policies across CDC that promote the elimination of health disparities; (3) assures implementation of proven strategies across CDC programs that reduce health disparities in communities of highest risk; (4) advances the science and practice of health equity; and (5) collaborates with national and global partners to promote the reduction of health inequalities.

Office of Women’s Health (CAWB). The mission of the Office of Women’s Health (OWH) is to provide leadership, advocacy, and support for the agency’s research, policy, and prevention initiatives to promote and improve the health of women and girls. As the agency’s leader for women’s health issues, OWH: (1) Advises the CDC Director and leads the Women’s Health Workgroup in the advancement of research, policies, and programs related to the health of women and girls; (2) provides leadership, assistance, and consultation to the agency’s centers, offices, and programs to address women’s health issues; (3) advances sound scientific knowledge, promotes the role of prevention, and works to improve the communication and understanding of women’s health priorities for public health action by CDC and a diverse group of state and local programs, providers, consumers, and organizations; (4) creates, publishes, and disseminates communicative products and materials that highlight CDC priorities, opportunities, and strategies to improve health; (5) establishes and fosters relationships with others (i.e., government agencies, professional groups, academic institutions, organizations and small businesses) to increase awareness and strengthen implementation of women’s health programs and practices; (6) represents the agency and serves as a liaison on women’s health issues within and outside the Department of Health and Human Services; and (7) coordinates and manages efforts through dialogues, meetings, and other activities to increase awareness of public health and women’s health issues.

Diversity and Inclusion Management Program (CAWCM). In carrying out its mission, the Diversity Management Program (DMP): (1) Provides and coordinates leadership for diversity issues CDC-wide; (2) ensures CDC’s diversity policies, procedures and practices support employees in reaching their full potential so that they may better accomplish CDC’s mission and be effective guardians of public health.

Sherri A. Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2013–30850 Filed 12–30–13; 8:45 am]
BILLING CODE 4160–18–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2013–N–0001]

Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Cellular, Tissue, and Gene Therapies Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the Agency on FDA’s regulatory issues.

Date and Time: The meeting will be held on February 25, 2014, from 8 a.m. to approximately 5:30 p.m. and February 26, 2014, from 8 a.m. to approximately 5 p.m.

Location: Hilton Washington, DC North/Gaithersburg, 620 Perry Pkwy., Grand Ballroom, Gaithersburg, MD 20877. The hotel’s phone number is 301–977–8700.

Contact Person: Gail Dapolito or Rosanna Harvey, Food and Drug Administration, Center for Biologics Evaluation and Research, 1401 Rockville Pike, HFM–71, Rockville, MD 20852; 301–827–1289 or 301–827–1297, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area). A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

Agenda: On February 25, 2014, from 8 a.m. to 5:30 p.m. and on February 26, 2014, from 8 a.m. to approximately 11:15 a.m., the committee will discuss oocyte modification in assisted reproduction for the prevention of transmission of mitochondrial disease or treatment of infertility. On February 26, 2014, from approximately 11:15 a.m. to 11:30 a.m., the committee will hear updates on guidance documents issued from the Office of Cellular, Tissue, and Gene Therapies, Center for Biologics Evaluation and Research (CBER), FDA. On February 26, 2014, from 1 p.m. to approximately 5 p.m., the committee will discuss considerations for the design of early-phase clinical trials of cellular and gene therapy products. CBER published guidance on this topic in July 2013 (http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/default.htm).

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the
appropriate advisory committee meeting link.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before February 18, 2014. Oral presentations from the public will be scheduled between approximately 2:15 p.m. and 3:15 p.m. on February 25, 2014 and between approximately 1:45 p.m. and 2:15 p.m. on February 26, 2014. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before February 10, 2014. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by February 11, 2014.

Persons attending FDA's advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Gail Dapolito at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 26, 2013.

Jill Hartzler Warner.
Acting Associate Commissioner for Special Medical Programs.